Loading…
Meihua Bio reported a 76.46% year-on-year decline in net profit for the first three quarters of 2026, while third-quarter profit fell 96%. Higher sales volumes were offset by lower prices for lysine and threonine; the company said growth in pharmaceutical-grade amino acids partly countered weaker revenue from its core products.
Lower lysine prices and expanded production are adding supply pressure, weighing on lysine prices. The company expects core product prices to be near a floor, but that recovery has not yet materialized.
caijing.hzdx.comNov 8, 2026Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.
